Autoimmune Hepatitis Market, By Type (Type 1, Type 2), Treatment (Medications, Liver Transplant, Others)to reach USD 210.61 million by 2029

In recent years, the autoimmune hepatitis market is anticipated to grow rapidly during the forecast period. According to the 2019 study "Burden of Liver Diseases in the World," liver illness causes roughly 2 million fatalities worldwide, with 1 million deaths due to cirrhosis complications and 1 million deaths due to viral hepatitis and hepatocellular cancer. Cirrhosis is the 11th most prevalent cause of mortality globally, while liver cancer is the 16th most common cause of death. They are responsible for 3.5 percent of all deaths worldwide.

View Detailed Report: https://www.databridgemarketresearch.com/reports/global-autoimmune-hepatitis-market

Data Bridge Market Research analyses that the autoimmune hepatitis market was valued at USD 156.76 million in 2021 and is expected to reach USD 210.61 million by 2029, registering a CAGR of 3.70% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Autoimmune hepatitis is a rare but deadly liver condition. The body assaults itself when it misidentifies healthy tissue and cells as infected tissue and cells, and antibodies are produced to attack the healthy liver cells. Autoimmune hepatitis can strike suddenly or progress gradually. The aetiology of the condition is unknown, but it may be linked to other systemic diseases or pharmaceutical exposure in some cases.

Some of the major players operating in the autoimmune hepatitis market are:

Pfizer Inc. (US)

GlaxoSmithKline plc (UK)

Novartis AG (Switzerland)

Mylan N.V. (US)

Teva Pharmaceutical Industries Ltd. (Israel)

Sanofi (France)

Boehringer Ingelheim International GmbH. (Germany)

AstraZeneca (UK)

Johnson & Johnson Private Limited (US)

Bayer AG (Germany)

Merck & Co., Inc. (US)

F. Hoffmann-La Roche Ltd. (Switzerland)

Bristol-Myers Squibb Company (US)

Cadila Pharmaceuticals (India) 

Eli Lilly and Company (US)

LEO Pharma A/S (Denmark)

Cipla Inc. (US)

Aurobindo Pharma (India)

Lupin (India)

Sumitomo Corporation (Japan)

Drivers

Rise in the prevalence of autoimmune hepatitis

The rising prevalence of autoimmune hepatitis is a major factor driving the autoimmune hepatitis market's growth rate. Enlarged veins in the oesophagus, fluid accumulation in the abdomen, liver failure, and liver cancer are some of the problems linked with such diseases. 

Explore More Reports:

https://manoj-mrr.blogspot.com/2024/03/steam-turbine-market-would-to-reach-usd_20.html

https://manoj-mrr.blogspot.com/2024/03/smart-grid-technology-market-to-undergo_20.html

https://manoj-mrr.blogspot.com/2024/03/medical-gloves-market-to-undergo-cagr_20.html

https://manoj-mrr.blogspot.com/2024/03/ready-mix-concrete-market-to-reach-usd.html

About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact Us:
Data Bridge Market Research
Tel: +1-888-389.80-2818 | +44 208 089 1725 | +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com

This release was published on openPR.